Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease

Back to Search
Print
Bookmark Trial

NCT00387270

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Huntington Study Group
Rochester, New York, 14620, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Huntington's Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Clinical features of Huntington's disease and a confirmatory family history of HD, or a CAG repeat expansion greater than or equal to 36

- Stage I,II,III HD and a total functional capacity greater than or equal to 5 on the Unified Huntington's Disease Rating Scale

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Clinical evidence of unstable medical illness

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Huntington's DiseaseStudy Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease
NCT01806896
  1. Paris Cedex 13,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Huntington's DiseaseRandomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
NCT02197130
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Phoenix, Arizona
  5. Scottsdale, Arizona
  6. Irvine, California
  7. Los Angeles, California
  8. Los Angeles, California
  9. Los Angeles, California
  10. Englewood, Colorado
  11. Gainesville, Florida
  12. Indianapolis, Indiana
  13. Charlestown, Massachusetts
  14. Saint Louis, Missouri
  15. Albany, New York
  16. Winston-Salem, North Carolina
  17. Cleveland, Ohio
  18. Cleveland, Ohio
  19. Columbus, Ohio
  20. Columbus, Ohio
  21. Columbus, Ohio
  22. Houston, Texas
  23. Vancouver, British Columbia
  24. Toronto, Ontario
  25. Montreal, Quebec
  26. Montreal, Quebec
  27. Munchen, Bavaria
  28. Aachen,
  29. Berlin,
  30. Bochum,
  31. Erlangen,
  32. Freiburg,
  33. Lubeck,
  34. Marburg,
  35. Münster,
  36. Taufkirchen,
  37. Ulm,
  38. Wuerzburg,
  39. Gdansk,
  40. Krakow,
  41. Poznan,
  42. Warszawa,
  43. Aberdeen, Aberdeenshire
  44. Southampton, Hampshire
  45. Oxford, Oxfordshire
  46. Sheffield, South Yorkshire
  47. Birmingham, West Midlands
  48. Cambridge,
  49. Cardiff,
  50. Glasgow,
  51. London,
  52. London,
  53. London,
  54. Manchester,
  55. Manchester,
  56. Newcastle Upon Tyne,
  57. Newcastle Upon Tyne,
ALL GENDERS
30 Years+
years
MULTIPLE SITES
Huntington's DiseaseOpen Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021
NCT02342548
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Scottsdale, Arizona
  4. Irvine, California
  5. Los Angeles, California
  6. Los Angeles, California
  7. Los Angeles, California
  8. Englewood, Colorado
  9. Gainesville, Florida
  10. Indianapolis, Indiana
  11. Saint Louis, Missouri
  12. Albany, New York
  13. Winston-Salem, North Carolina
  14. Columbus, Ohio
  15. Columbus, Ohio
  16. Columbus, Ohio
  17. Houston, Texas
  18. Vancouver, British Columbia
  19. Toronto, Ontario
  20. Montreal, Quebec
  21. Montreal, Quebec
  22. Aachen,
  23. Berlin,
  24. Bochum,
  25. Erlangen,
  26. Lübeck,
  27. Marburg,
  28. Munchen,
  29. Münster,
  30. Taufkirchen,
  31. Ulm,
  32. Wuerzburg,
  33. Gdansk,
  34. Krakow,
  35. Poznan,
  36. Warszawa,
  37. Oxford Road, Manchester
  38. Gosforth, Newcastle UPON TYNE
  39. Birmingham, WEST Midlands
  40. Aberdeen,
  41. Cardiff,
  42. Glasgow,
  43. London,
  44. London,
  45. London,
  46. Manchester,
  47. Newcastle upon Tyne,
  48. Oxford,
  49. Sheffield,
  50. Southampton,
ALL GENDERS
30 Years+
years
MULTIPLE SITES
Huntington's DiseaseA Study of the Novel Drug Dimebon in Patients With Huntington's Disease
NCT00497159
  1. Rochester, New York
ALL GENDERS
29 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease
Official Title  ICMJE A Multicenter, Phase 1-2A, Open-Label, Dosage-Escalation and Randomized, Double-Blinded, Placebo-Controlled Study of Dimebon in Subjects With Huntington's Disease
Brief Summary This study is being conducted to determine the safety and tolerability of Dimebon in people with Huntington's disease after short-term exposure (one week) and after longer exposure (three months). Also, the study will assess whether or not there is an effect of Dimebon on the symptoms of Huntington's disease, including cognitive (thinking abilities), motor (movement), behavior, and overall functioning.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Huntington's Disease
Intervention  ICMJE Drug: Dimebon
Dimebon 10 or 20 mg TID x 7 days
Study Arms  ICMJE Experimental: A
Dimebon
Intervention: Drug: Dimebon
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: January 3, 2008)		9
Original Enrollment  ICMJE
 (submitted: October 10, 2006)		75
Actual Study Completion Date  ICMJE March 2007
Actual Primary Completion Date March 2007   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Clinical features of Huntington's disease and a confirmatory family history of HD, or a CAG repeat expansion greater than or equal to 36
  • Stage I,II,III HD and a total functional capacity greater than or equal to 5 on the Unified Huntington's Disease Rating Scale

Exclusion Criteria:

  • Clinical evidence of unstable medical illness
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00387270
Other Study ID Numbers  ICMJE DIM03
DIMOND
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Karl Kieburtz, MD, Clinical Trial Coordination Center
Study Sponsor  ICMJE Medivation, Inc.
Collaborators  ICMJE Huntington Study Group
Investigators  ICMJE
Principal Investigator:Karl D Kieburtz, MDUniversity of Rochester Medical School, Huntington Study Group
PRS Account Medivation, Inc.
Verification Date September 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP